Holen Sie sich die Stockscreener-App
23.30
2.55%
-0.61
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx Pharmaceutical Inc. $RARE Stock Position Cut by SG Americas Securities LLC - MarketBeat
Rep. Gilbert Ray Cisneros, Jr. Buys Ultragenyx Pharmaceutical Inc. Shares - National Today
Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data - MSN
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings call transcript - MSN
Ultragenyx Pharmaceutical stock (US74930A1043): Is its rare disease pipeline strong enough to unlock - AD HOC NEWS
Is Ultragenyx Pharmaceutical (RARE) Pricing Reflect Its Long Term Potential After 5 Year Slump - Yahoo Finance
FDA Accepts Ultragenyx’s New BLA Submission for MPS IIIA Gene Therapy UX111 - CGTLive®
Rep. Gilbert Ray Cisneros, Jr. Buys Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares - MarketBeat
RARE DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class ActionRARE - ACCESS Newswire
Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Reminds Ultragenyx Investors ... - Bluefield Daily Telegraph
Ultragenyx Pharmaceutical Inc. Class Action: Levi & - GlobeNewswire
RARE Rises as FDA Accepts Resubmitted BLA for Sanfilippo Syndrome - The Globe and Mail
ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. - GlobeNewswire
ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm - GlobeNewswire Inc.
RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - 巴士的報
FinancialContentRARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - FinancialContent
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - Finansavisen
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - Finansavisen
RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical ... - Caledonian Record
RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026RARE - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx - GlobeNewswire
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - Finansavisen
Aberdeen Group plc Buys 496,295 Shares of Ultragenyx Pharmaceutical Inc. $RARE - marketbeat.com
Ultragenyx Pharmaceutical Hits 52-Week Low at $18.29 Amidst Declining Performance - Markets Mojo
RARE Deadline: RARE Investors with Losses in Excess of $100K Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - Lelezard
RARE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - PR Newswire
RARE Deadline: RARE Investors with Losses in Excess of $100K Hav - GuruFocus
Ultragenyx says gene therapy accepted for FDA review again - MSN
Ultragenyx EVP Pinion sells $228k in shares - Investing.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Ultragenyx Faces Lawsuit Deadline for Investor Losses - National Today
Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of - PharmiWeb.com
Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.RARE - The AI Journal
Rosen Law Firm Urges Ultragenyx Shareholders to File Claims - National Today
Mereo BioPharma Faces Deadline for Shareholder Vote - National Today
RARE Deadline: Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Business Wire
DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ - marketscreener.com
Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) - Bitget
ULTRAGENYX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important April 6 Deadline in Securities Class ActionRARE - ACCESS Newswire
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceuti - GuruFocus
Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Re - GuruFocus
FDA accepts Ultragenyx gene therapy application for rare disease By Investing.com - Investing.com Australia
Ultragenyx CFO Horn Howard sells $98k in shares By Investing.com - Investing.com India
Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells 4,683 Shares of Stock - marketbeat.com
Ultragenyx CFO Horn Howard sells $98k in shares - Investing.com
Ultragenyx (RARE) CFO sells 4,683 shares, retains 80,351 stake - Stock Titan
ULTRAGENYX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, - GlobeNewswire
Morgan Stanley reiterates Ultragenyx stock rating on FDA filing progress By Investing.com - za.investing.com
Morgan Stanley reiterates Ultragenyx stock rating on FDA filing progress - Investing.com
Ultragenyx (RARE) Moves Forward with FDA Review of Gene Therapy Application - gurufocus.com
0.95%
3.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):